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ABSTRACT
EFFECTS OF DEVELOPMENTAL EXPOSURES OF TWO EMERGING
ENVIRONMENTAL TOXICANTS ON ESTROGEN-SENSITIVE ENDPOINTS
MAY 2015
CORINNE E. HILL, B.S., UNIVERSITY OF ALBANY
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Laura N. Vandenberg

Background: Humans have created thousands of synthetic chemicals that are released
into the environment, causing widespread exposures of wildlife and humans alike. Some
of these chemicals are known to disrupt one or more aspects of hormone action, with a
subset inducing abnormalities in endocrine related tissues and organs such as the
reproductive system. Bisphenol S (BPS) and tetrabromobisphenol A (TBBPA) are two
chemicals commonly used in consumer products and are suspected to have endocrine
disrupting properties based on their similar chemical structures to known endocrine
disrupting chemicals (EDCs).
Objectives: To determine whether perinatal exposure to BPS or TBBPA induced
abnormalities in ovarian and uterine tissue at the organ, tissue, cellular or molecular
levels of biological organization.
Methods: Pregnant female mice were administered vehicle, BPS or TBBPA during
pregnancy and lactation. From postnatal day (PND) 19-21, two female offspring from
each litter were administered either oil or ethinyl estradiol, and killed at PND22. One
additional female per litter was killed at week 16. The reproductive tracts were examined
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for gross morphological defects and then fixed and frozen for basic histological,
immunohistological and gene-expression assessments.
Results: Our study identified significant differences in ovarian follicular formation and
gene expression after developmental exposures to BPS or TBBPA. Most effects were
observed at PND22, and were apparent after an estrogen challenge; however, these
differences were not observed at 16 weeks of age suggesting that changes induced by
BPS and TBBPA are age dependent.
Conclusions: Our results suggest that TBBPA and BPS alter development of the female
reproductive tracts, with the most obvious effects on the pre-pubertal ovary after
developmental BPS treatment. These findings are among the first to examine the effects
of these two chemicals and indicate that widespread exposures to BPS and TBBPA may
have implications for public health. Further, evidence regarding negative health effects
after animal exposures to widely available EDCs may explain the global increase in
female reproductive health abnormalities in humans.
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CHAPTER 1
INTRODUCTION
1.1 Introduction to Endocrine Disrupting Chemicals
Today, both humans and wildlife live in an environment that contains a multitude
of man-made chemicals which have been produced for use as pesticides, industrial
compounds, in personal care products, fertilizers, plastics and other packaging materials,
pharmaceuticals, and others. Unfortunately, these compounds can have unintended health
outcomes on biota. Subsets of these chemicals are capable of mimicking or interfering
with the actions of hormones and thus cause disturbances within the endocrine systems of
exposed humans and animals. When disturbances to hormone signaling processes cause
adverse health effects in the organism itself or in its offspring, they are referred to as
endocrine disrupting chemicals (EDCs) (Bergman et al. 2013). In 2009, the Endocrine
Society described EDCs as “compounds, either natural or synthetic, which through
environmental or inappropriate developmental exposures alters the hormonal and
homeostatic systems that enable the organism to communicate with and respond to its
environment” (Diamanti-Kandarakis et al. 2009). In 2012, the Endocrine Society
simplified this definition, describing an EDC as “an exogenous chemical, or mixture of
chemicals, that can interfere with any aspect of hormone action” (Zoeller et al. 2012) The
concept of “hormone action” was further described as the ability of an exogenous
chemical to activate a hormone receptor either directly or indirectly resulting in
physiological effects (Zoeller et al. 2014).
The majority of EDCs that are present in the environment are products of human
manufacturing; however, there are also naturally occurring substances that are able to
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disrupt endocrine pathways. These natural EDCs include metals such as arsenic,
cadmium, lead and mercury; natural hormones such as estradiol and testosterone excreted
from animals and humans; and phytoestrogens such as isoflavonoids and coumestans
derived from plants (Bergman et al. 2013). Although these naturally occurring EDCs
have potential adverse effects that should be accounted for, and in fact there are
documented examples of these natural EDCs disrupting reproductive health,
anthropogenic EDCs pose threats to human and wildlife health while providing important
paths for public health interventions. This report will focus solely on anthropogenic
EDCs.
The field dedicated to the study of EDCs is fairly new, and in fact the term
‘endocrine disruptor’ was first coined in 2001 (Vandenberg et al. 2015). Up until the
early 2000s, the majority of knowledge concerning compounds that interfere with
hormone signaling was based on studies involving chemicals created for and used in
industry, agriculture and pharmaceuticals. These studies focused on a very limited
number of environmentally persistent organic pollutants (POPs) such as polychlorinated
biphenyls (PCBs), dichlorodiphenyltrichloroethane (DDT) and polychlorinated
dibenzofurans (PCDFs), which are reviewed in (Bergman et al. 2013). Apprehension
within the scientific community toward these anthropogenic compounds and others did
not begin to rise until a series of unusual phenomena relating man-made chemicals to the
decline of human, plant and wildlife wellbeing started appearing. The earliest of these
occurrences involved the use of synthetic chemicals such as diethylstilbestrol (DES) in
the 1930s-1970s, PCBs from 1929-1980s and DDT produced from the 1940s through the
present time ( Li and Macdonald 2005; Marty et al. 2011). Extensive studies surrounding
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these chemicals, and the growing field of biomonitoring and exposure science, sparked a
realization that the number of EDCs that one may encounter on a daily basis is
astronomically greater than what was expected in past years, and that sources of
exposures may vary greatly (Needham et al. 2005; Needham et al. 2008; Woodruff et al.
2011). Within the past decade, it has been revealed that EDCs originate from a wide
range of sources including additives in consumer goods and materials such as cosmetics
and other personal care products, food packaging, cleaning products, plastics and
pesticides, among others. For years, this wide range of commercially available chemicals
was excluded from the scope of scientific and health related concern because of
expectations that these chemicals were well tested for toxicity. Currently, although the
criteria for characterizing compounds as EDCs differs somewhat by different groups,
more than 1000 compounds are listed as putative EDCs in the US FDA’s Endocrine
Disruptor Knowledgebase and on lists maintained by groups such as the Endocrine
Disruptor Exchange (Vandenberg et al. 2013b).
The incidence of chronic diseases such as certain cancers, diabetes, obesity, and
cardiovascular disease (among many others) are increasing at alarming rates and are
collectively the leading causes of illness and death globally, surpassing communicable
disease rates even in developing countries (Barouki et al. 2012; WHO 2011). According
to the WHO, the expected number of annual cancer cases worldwide will increase from
14 million in 2012 to 22 million within the next 2 decades. In many instances, factors
such as genetics, nutrition and lifestyle are not able to fully explain these striking
increases in chronic disease. Despite this lack of etiological explanations, research
conducted in wildlife and laboratory animal populations point to environmental factors
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such as chemical exposures as likely contributors to rising incidences of chronic diseases.
It is important to recognize the burden that these diseases place on societies worldwide.
The increasing rates of chronic disease pose concerns for public health agencies as they
drive the need for increased medical attention and services. Costs that accompany health
care required to treat these diseases put drastic stress on economies; for example, it is
estimated that global spending on diabetes alone is expected to rise to $490 US billion in
2030, which is 12% of all health care spending (Zhang et al., 2010). Increased spending
on health care related to chronic illness and diseases is referred to as the “global burden
of disease” and is among the current leading public health concerns globally.
There are a few key factors that designate EDCs as environmental health
concerns. First, as stated above, EDCs have the ability to interact with normal hormonal
processes and functions within an organism, potentially causing disturbances in major
physiological systems such as development and reproduction, resulting in adverse health
effects. Second, although not true of every EDC, many of these compounds tend to be
lipophilic molecules, and thus are efficiently stored in fat deposits and fluids of the body
at a faster rate than they are excreted, a process known as bioaccumulation. In pregnant
females, these lipophilic substances can be passed to neonates by crossing the placental
barrier, thus exposing the fetus to a variety of concentrations and mixtures of potentially
hazardous components (Barr et al. 2007). Lastly, many EDCs and/or their byproducts
have the ability to accumulate with increasing order within the food chain, a process
known as biomagnification, which allows these chemicals to accumulate in adipose tissue
of living organisms and persist long after the chemical was first released into the
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environment. This process produces the most risk to organisms at the top of the food
chain such as humans and other high-order carnivorous species.

1.2 Bisphenol S and Tetrabromobisphenol A
Bisphenol S (BPS) is a chemical that is structurally similar to Bisphenol A (BPA) (Figure
1), a known EDC that has been shown to induce adverse effects at low doses, especially
in reproduction and developmental outcomes (Richter et al. 2007; Rochester 2013;
Vandenberg et al. 2010; Vandenberg et al. 2013a). BPA is predominantly used in the
production of polycarbonate plastics, both of industrial and consumer grade; thermal
papers commonly used for receipt paper; epoxy linings of food and drink containers; as
well as other various consumer and industrial products including toys, medical
equipment, and sports safety equipment, among others (Geens et al. 2012; Huang et al.
2012). Human exposure to BPA occurs predominantly by two routes of exposure:
absorption through the skin or by ingestion; inhalation may also be possible as BPA is
found in air and dust samples (Vandenberg et al. 2013a). BPA is an extremely lipophilic
molecule allowing it to be absorbed through the skin by mere contact with items
containing BPA, such as thermal receipt paper (Biedermann et al. 2010; Zalko et al.
2011). Additionally, BPA leaches out of food and drink packaging and enters the body
via ingestion (Vandenberg et al. 2007).
Over the past decade, public knowledge regarding adverse outcomes related to
BPA exposure has increased, resulting in consumers’ unwillingness to buy products
containing this compound. To appease consumer concerns, industries such as the largest
thermal receipt paper supplier in the US have begun to replace BPA with other related
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chemical, such as thermal receipt paper (Porras et al. 2014). BPS also leaches out of food
and drink packaging and enters the body via ingestion (Bittner et al. 2014; Ozaki et al.
2004) and is also present in dust, which can ultimately enter the body through ingestion
(Liao et al. 2012b).
As discussed elsewhere (Vandenberg et al. 2015), the introduction of BPS to the
consumer market as a replacement of BPA may be an example of a regrettable
replacement, where one compound is phased out and another with toxicity is used in its
place. If BPS does have endocrine disrupting properties, this would be an emerging
public health concern as approximately 81% of humans have traceable levels of BPS
metabolites in their urine; Japan and the US have the highest BPS detection frequencies
which may be attributed to the replacement of BPA with BPS in these two countries
(Liao et al. 2012a).
Tetrabromobisphenol A (TBBPA) is also a chemical derivative of BPA created by
brominating BPA in an organic solvent (Figure 1). TBBPA is used as a reactive flame
retardant that is chemically bound to epoxy and polycarbonate resins used in the
manufacturing of electronic circuit boards and textile adhesives, and is used worldwide
(Alaee et al. 2003). The purpose of flame retardants is to decrease a product’s chance of
igniting. Because this compound is released or shed from many consumer products,
TBBPA is present in indoor air, dust and river sediment; it enters the body through oral
ingestion via dust particles or from contaminated food or water (Butte and Heinzow
2002; Oberg et al. 2002).
There are two main concerns regarding TBBPA and its effects on health. The first
concern is that TBBPA, like BPS, is structurally similar to BPA; as structure is often
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predictive of biological action, it has been hypothesized that it has the potential to act as
an EDC. The second concern is that TBBPA is persistent in the environment due to its
bromine groups which allows TBBPA to bioaccumulate within the body including blood
and adipose tissue (Jakobsson et al. 2002; Shen et al. 2012; Thomsen et al. 2001). One
study observed biomagnification of TBBPA up through wild herring gull food chains and
also detected TBBPA in herring gull eggs, consistent with the substance’s persistence in
the environment (Letcher and Chu 2010). A human study of French mothers found
concentrations of TBBPA ranging from 0.062 to 37 ng/g fat in breast milk (Cariou et al.
2008). More recently, TBBPA was found in breast milk of a cohort of Japanese women at
concentrations of 0.14 to 8.7ng/g lipid (Nakao et al. 2015). These examples emphasize
that exposures to TBBPA can occur in developing young in both wildlife and human
populations. Similar to BPS, controlled exposure assessments regarding TBBPA and
resulting health outcomes remain largely unstudied.
Despite meager data available that examines adverse health effects induced by
BPS and TBBPA, some recent studies suggest that these two compounds have endocrine
disrupting properties. Molina-Molina et al. observed that BPS and TBBPA are able to
disrupt multiple nuclear receptors in vitro and therefore may have the ability to interfere
with the endocrine system (Molina-Molina et al. 2013). BPS was found to be an agonist
for both estrogen receptor  (ER) and estrogen receptor  (ER) and TBBPA was
found to be a weak agonist for human pregnane X receptor (PXR). This study also
revealed that BPS but not TBBPA was able to stimulate cell proliferation in MCF-7 cells
and inhibit proliferation of MCF-7 AR1 cells. These findings suggest that BPS has
estrogenic and androgenic properties and is able to induce estrogen and androgen
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dependent outcomes, whereas TBBPA is able to induce xenobiotic detoxification through
binding with PXR. However, this study did not observe estrogen regulation effects
associated with TBBPA exposure. In contrary, Olsen and colleagues found that TBBPA
was able to bind to estrogen receptor isolated from MCF-7 cells, increase levels of
estrogen-regulated proteins and induce progesterone receptor (Olsen et al. 2003). Finally,
although studies of BPS in mammals are limited, studies in zebrafish support the
hypothesis that this chemical can disrupt both reproductive and developmental endpoints
(Ji et al. 2013; Kinch et al. 2015; Naderi et al. 2014).

1.2.1 Regulation of BPS and TBBPA
In 1995, the United Nations Environment Programme (UNEP) called for a global
recognition and action against further production of persistent chemicals. In 2001, an
international environmental treaty known as “The Stockholm Convention” composed
guidelines for a select group of chemicals, coined POPs (persistent organic pollutants),
which are known to be highly persistent and are capable of long distance transport in the
environment. These guidelines set a plan to regulate, reduce and/or completely
discontinue the use and production of these compounds. In theory, the Stockholm
Convention would apply to TBBPA however; TBBPA is not currently listed as a POP in
the Stockholm Convention. In fact, TBBPA is the primary flame retardant used
worldwide, accounting for 58.7% of total brominated flame retardant use.
The use of BPS in consumer products is currently increasing due to restrictions
put in place by the US Environmental Protection Agency (USEPA), Health Canada, and
the European Food Safety Authority (EFSA) that limit the use of BPA in consumer
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products (Kinch et al. 2015). Heightened consumer knowledge and concern regarding the
use of BPA in consumer products also drives product manufacturers to replace BPA with
BPS in order to produce “BPA-free” items, thus ameliorating consumer demand for
“safer” alternatives. Currently, no US government agency tests for toxicity of new
materials before they are used in consumer products and released to the public (Kinch et
al. 2015).
The use of TBBPA and BPS in consumer products is largely unregulated
worldwide. Due to the lack of control regarding the use of these chemicals, items
containing BPS and TBBPA continue to be available to consumers, leading to
widespread human exposures to these two environmental toxicants.

1.3 The issue of risk assessment
The risk assessment process involves four steps: first, hazard identification
requires that the biological/toxicological effects of a compound are assessed, typically
using standard protocols. Next, dose response assessments are performed, allowing for
the prediction of specific hazards at specific doses, as well as the prediction of hazards at
doses that were not tested. In the third step, exposure assessments are conducted; this
process allows for the identification of sources and routes of exposure. Finally, the data
from these first three steps is combined in a risk characterization process, and the risk to
the population is estimated.
Risk assessment is often criticized as a non-scientific process, particularly
because of studies showing that risk assessment decisions rely on ‘expert judgment’ and
are often not reproducible (Frumkin 2005). Risk assessments for EDCs have also been
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challenged, although the issues that influence assessments for this class of compounds
differ somewhat from the concerns that have been raised regarding risk assessments in
general. These matters are discussed in some depth below.
First, traditional risk assessments operate under the assumption that all chemicals
act through a linear dose-response mechanism. This theory encompasses an expectation
of increasing response for a set endpoint with increasing concentration of chemical in a
linear fashion. Under this assumption, not only are higher doses expected to induce
greater effects, there is an assumption that the effects at lower doses can be predicted
based on high dose studies. Importantly, this “one model fits all” ideology should be
applied to all types of chemicals when assessing associated risks. It has been shown that
natural hormones as well as EDCs can defy the expectation of linear or monotonic dose
response curves, and instead can include more complicated, non-linear dose responses
including non-monotonic dose responses curves (NMDRCs). The term NMDRC simply
means that the slope of the dose response curve changes from positive to negative or visa
versa at some point of change in dose, usually resulting in a U-shaped or inverted Ushaped dose-response curve. This topic has been reviewed in detail by Vandenberg and
colleagues (Vandenberg et al. 2012).
Hormones act via high-affinity binding to specific proteins known as receptors.
Downstream effects of hormones are induced when a hormone successfully binds to a
receptor and activates a cascade of cellular events including gene transcription. Hormone
receptors are limited and present only in specific cells and tissues within an organism. If
receptors are not present, hormones will not have the ability to act or induce a response.
Considering these hormone-receptor interactions, there are a number of mechanisms that
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have been characterized, largely by endocrinologists, to explain how hormones and EDCs
can induce NMDRCs. One mechanism is explained by the non-linear relationship
between hormone concentration, number of bound receptors, and biological effects
(Welshons et al. 2003). Due to limited number of hormone receptors, receptors become
saturated when hormone concentrations are high. In this case, response is not solely
dependent upon the concentration of hormone but also dependent upon the number of
bound receptors as response is dictated by the number of bound hormone-receptor
complexes; the greater the number of bound hormone-receptor complexes, the greater the
magnitude of response.
Other factors that can contribute to the manifestation of a NMDRC have also been
described. The first of these factors is the possibility of receptor down-regulation in the
presence of a high concentration of hormone. At high hormone concentration, the rate of
receptors lost (due to movement of bound receptors to other sites within the cell such as
the nucleus) is greater than the rate of receptor replenishment, resulting in a responselimiting factor. Another factor that contributes to NMDRCs is the ability of some
hormones to bind to multiple different types of receptors; this affinity to different
receptors is typically based on the concentration of hormone. In this case, at low
concentrations the hormone may only bind to receptors that have a very high affinity for
that particular hormone whereas at high hormone concentrations the hormone may also
bind to receptors that have a lower affinity for that particular hormone; the resulting
observed response is due to the hormone binding with multiple classes of receptors.
Endogenous estrogens and xenoestrogens both follow this receptor affinity factor
and can produce NMDRCs. An example of this factor is illustrated by the response of
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estrogen dependent breast cancer cells that are treated with Tamoxifen, resulting in what
is known as “Tamoxifen flare”. At low doses of Tamoxifen, breast cancer cells
proliferate, but as concentrations increase in the blood, the “therapeutic range” is
achieved, and cancer cells stop proliferating. At higher doses, apoptosis is induced in
these cancer cells, and at even higher concentrations, Tamoxifen induces systemic
toxicity. In this example, the least toxicity is observed at a moderate dose of the drug
(Reddel and Sutherland 1984).
Another related issue that has challenged traditional risk assessment methods is
the ability of EDCs to induce adverse effects even when exposures occur at low doses or
concentrations. Although the term “low dose” has many different definitions, the
National Toxicology Program (NTP) defines low dose effects as “ any biological changes
1) occurring in the range of typical human exposures or 2) occurring at doses lower than
those typically used in standard testing protocols” (Melnick et al. 2002). As mentioned
above, a biological response can occur only when a hormone successfully binds to its
receptor. Low dose effects are possible because receptors are rarely if ever saturated,
meaning that even low concentration of hormone or EDC can increase the number of
receptors bound, resulting in maximal response even at a low dose.
Finally, the method used to assess the effects of EDCs have been challenged, with
some suggesting that the endpoints examined in traditional guideline studies are not
relevant to human diseases of concern (Myers et al. 2009a; Myers et al. 2009b). In risk
assessments, EDCs are typically treated the same as every other chemical, i.e. assumed to
have general toxicity, and assessed based on the linear response model. If chemicals that
act as hormone receptor agonists are only tested at doses where a traditional toxic
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response (i.e. death, loss of body weight) is expected based on the linear response model,
entire responses are left unassessed at lower doses. Unfortunately, this reliance on an
expectation of a monotonic dose response may leave entire groups of chemicals such as
potential EDCs inadequately assessed.

1.4 The ovary
The ovaries are essential female organs that carry out crucial roles in both the
endocrine and reproductive systems. The ovaries house germ cells and also generate and
release multiple steroidal and non-steroidal hormones directly into the blood stream;
these hormones play important roles in endocrine feedback systems. Mammalian females
possess a maximum number of germ cells or oocytes at birth. Their numbers continually
decrease after birth until all oocytes have been ovulated or have died via various
apoptotic pathways; when all oocytes have been expended, the female enters a period
known as menopause. Human females are born with approximately 2 million primordial
oocytes; by the time puberty is reached, only about 400,000 remain (Kovacs and Ojeda
2011). The number of primordial oocytes present in mouse ovaries is highly debatable
because follicle counting methods involve a great amount of error and numbers vary
greatly depending on the strain of animal and methods used (Tilly 2003). The total
estimated number of follicles in the mouse ovary reported varies from 3,500 to 30,000
(Pepling and Spradling 2001).

1.4.1 Follicle development
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At birth, the oocytes present in the ovary are known as primary oocytes. These
primary oocytes undergo stages of follicle maturation based on changes in concentration
of gonadotropins, luteinizing hormone (LH) and follicular stimulating hormone (FSH),
which are released from the anterior pituitary. Ovulation in humans is regulated by a
cyclic mechanism known as the menstrual cycle; one oocyte is ovulated approximately
every 29.5 days. Ovulation in the mouse follows a different pattern known as the estrus
cycle; environmental cues such as amount of light signal ovulation of multiple oocytes
(Gilbert 2010a). The first phase of follicle development is categorized by a series of
developmental maturation steps where follicles can be categorized as follows: 1)
Primordial follicles include primary oocytes surrounded by a flat layer of epithelial cells.
2) Primary follicles contain the oocyte and a single or double layer of granulosa cells that
are formed from the epithelial cells. Granulosa cells have FSH receptors and their main
function is to convert androgens to estradiol. 3) Secondary follicles contain the oocyte
surrounded by more than two layers of granulosa cells and an outer layer of theca cells
that are derived from stromal cells. Theca cells have LH receptors and produce
androstenedione, which is used by granulosa cells to convert androgens to estradiol. 4)
Antral (or graafian) follicles contain the oocyte surrounded by two or more layers of
granulosa cells, outer theca cell layers and contain a large follicular fluid filled
compartment known as the antrum (with a high concentration of steroids and local
growth factors).
After follicular maturation is complete, the second stage of the follicular phase
begins. In this second phase, mature follicles become dominant and each mature follicle
expels its ovum into the fallopian tube where it can be fertilized in a process known as
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development in a mouse ovary. An image showing the histological appearance of a
corpus luteum is also shown.

1.4.2 Development of the ovary/oogenesis
The ovary and the female germ-line undergo development during prenatal and postnatal
development, and are marked by two rounds of meiosis. In mice, primordial germ-cells
migrate to the ovaries at approximately days 7-11 of gestation, and germ-cell meiosis I
begins at gestational day 13, when germ-cells begin to proliferate and develop into
primordial follicles and follicles (Borum 1961; Smith et al. 2014). Primordial germ-cells
assemble within the ovary into what is referred to as the “follicle reserve” or “oocyte
nest” (Kerr et al. 2013; Uzumcu et al. 2012). In humans, the process of primordial follicle
assembly occurs during gestation and is complete by birth whereas in rodents, primordial
follicle reserves do not completely form until postnatal day 2-3 (Kerr et al. 2013). These
reserves contain a finite number of primordial follicles that will either mature through the
stages of follicular development (discussed in Section 1.4.1) and ovulate or will die
throughout an individuals’ lifespan; about 99.9% of growing follicles are atretic (Uzumcu
et al. 2012). Ultimately, the number of viable primordial follicles present at or near birth
dictates the length of the reproductive life span. These primordial follicles remain
inactive in meiotic arrest of the diplotene stage of prophase I until puberty, when groups
of primordial follicles begin follicular growth. At puberty, LH surges from the pituitary
will signal select primordial follicles to continue and complete meiosis I. When the
follicles mature into a secondary follicle, meiosis II begins but halts at metaphase.
Further continuation of meiosis II can only be completed if fertilization occurs. In the
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human, some oocytes remain in meiotic prophase arrest for nearly 50 years (Gilbert
2010b).

1.4.3 Ovarian steroid hormones
There are three key families of hormones that are essential for the control and
maintenance of ovarian maturation as well as endocrine feedback loops that involve the
ovary. These families include estrogens, androgens and progestins. The primary estrogen
secreted by the ovary is 17β-estradiol (E2). In the ovary, E2 primarily acts via binding to
estrogen receptor (ER)-, which is present in granulosa cells. E2 induces proliferation and
decreases apoptosis of granulosa cells, as well as maintains FSH responsiveness and
creates LH receptors. Testosterone is the primary androgen that participates in ovarian
feedback loops. Testosterone binds to androgen receptors (AR), which are present in
granulosa cells and increases E2 and progesterone secretion through FSH stimulation.
Progesterone is the major hormone in the progestin family. Like AR and ER,
progesterone receptors (PR) are expressed in granulosa cells. Progesterone, known as the
“pregnancy hormone”, inhibits E2 production that is induced by FSH (Kovacs and Ojeda
2011). These three classes of hormones are responsible for follicular development
(discussed above) as well as for providing input needed to control other endocrine
hormones outside of the ovary.

1.4.4 The hypothalamic-pituitary-ovarian (HPO) axis
Female reproductive hormones are regulated by a system of endocrine organs
including the hypothalamus, the anterior pituitary gland, and the ovaries, known as the
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E2 acts directly on both the hypothalamus and the anterior pituitary to inhibit
hormone secretion. E2 secreted from the ovaries inhibits secretion of gonadotropin
releasing hormone (GnRH) from the hypothalamus by binding to ER, thus suppressing
GnRH neurons in the arcuate nucleus. E2 also acts on the anterior pituitary by suppressing
gene expression of the LH -subunit, which inhibits the release of LH. Inhibition of
hormone synthesis by the hypothalamus and pituitary decreases circulating
concentrations of GnRH and LH, resulting in decreased production of E2, which is
typically derived from androstenedione by thecal cells of the ovary (Kovacs and Ojeda
2011). Inhibition of GnRH, LH and E2 via this system completes the negative feedback
loop, which can be carried out within minutes.
Positive feedback of the HPO axis is also controlled predominantly by ovarian E2
but occurs only during the follicular development phase of the menstrual or estrous cycle.
As follicles mature, they produce more E2, which stimulates increased GnRH release
from the hypothalamus and increased FSH and LH release from the anterior pituitary.
Positive feedback continues throughout the follicular phase, building increasing
concentrations of E2, FSH and LH until an LH surge, which is responsible for ovulation,
occurs. Promptly after ovulation, positive feedback ceases as E2 secretion is inhibited by
progesterone that is secreted by the corpus luteum. If pregnancy fails to occur, positive
feedback of the HPO axis will resume when the luteal phase is completed. Contrary to the
rapid response of the HPO axis’ negative feedback system, a delay lasting several hours
occurs before E2 is able to induce the positive feedback system (Kovacs and Ojeda 2011).

1.4.5 Diseases of the ovary
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A few ovarian diseases are responsible for the majority of ovarian dysfunction
including polycystic ovary syndrome (PCOS), ovarian cancer, ovarian cysts and
premature ovarian failure. Of these ovarian complications, PCOS is the most abundant
endocrine related abnormality in women of reproductive age, affecting up to 18% of the
female population (March et al. 2010). The etiology of PCOS is unknown, however those
diagnosed with PCOS have increased prevalence of insulin resistance and obesity, which
further increases risk of developing type II diabetes and cardiovascular disease (Shaw et
al. 2008). Due to a multitude of phenotypes associated with PCOS including
oligomenorrhoea/amenorrhoea, clinical or biochemical hyperandrogenism and polycystic
ovaries detected by ultrasound, debate surrounds PCOS diagnostic criteria (Azziz et al.
2009). In addition to the increased risk of developing chronic diseases, PCOS is also
responsible for reproductive dysfunction. The majority of women with PCOS (70-80%)
experience oligomenorrhoea, infrequent menstruation; or amenorrhoea, absence of
menstruation (Brassard et al. 2008). PCOS is the leading cause of annovulatory infertility
striking up to 95% of women with annovulation (Teede et al. 2010). PCOS disrupts the
HPO axis by increasing production and secretion of ovarian androgens, which impairs
ovarian follicle development; excessive androgens induce other undesirable outcomes
including excessive hair growth (Teede et al. 2010). Ovarian cysts can occur either as a
result or independently from PCOS diagnosis. Ovarian cysts are fluid filled sacs found
either in or on the surface of the ovary that can cause abdominal pain but often times are
not related to any symptoms or negative health effects (Conway et al. 2014). Increased
research and understanding of PCOS is needed to improve diagnostic and treatment
implications. For example, because global increases in obesity rates are tightly related to
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increasing PCOS rates, PCOS is a complicated public health issue resulting in an
abundance of adverse health and reproductive outcomes (Shaw et al. 2008).
According to the American Cancer Society, ovarian cancer accounts for the most
number of deaths out of all cancers of the female reproductive system. It is estimated that
in 2015, more than 20,000 women will be diagnosed with ovarian cancer (American
Cancer Society 2014). Like PCOS, the etiology of ovarian cancer is unknown; very few
cases can be linked to genetic heredity leaving the majority of ovarian cancer cases
sporadic (Doufekas and Olaitan 2014). Although epidemiological studies have revealed
risk factors such as: age, genetic mutations in the BRCA1 and BRCA2 genes, previous
endometriosis or breast cancer diagnosis, lack of parity, and others, these factors cannot
fully explain the incidence of ovarian cancer observed today (Doufekas and Olaitan
2014). It is known that certain DNA or gene mutations can induce the growth of
cancerous cells. The majority of the genetic mutations associated with ovarian cancer are
not inherited but rather acquired throughout a woman’s life. Genetic mutations can result
from environmental exposures to radiation or carcinogenic chemicals; importantly,
specific chemicals present in the environment have not yet been linked to mutations that
result in ovarian cancer (American Cancer Society 2014).
Premature ovarian failure (POF) is defined as premature amenorrhea with
elevated gonadotrophin levels observed under the age of 40; POF is commonly referred
to as ‘premature menopause’ (Haller-Kikkatalo et al. 2015). Like PCOS, the cause of
POF is unknown and many factors contribute to the diagnosis of this disease. Yet,
diagnostic criteria vary and can involve assessments using ultrasound, bone mineral
density, and serum E2 and FSH levels (Conway et al. 1996). Given the heterogeneity of
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POF diagnostic methods, it is extremely difficult to study its prevalence; therefore
estimates of POF prevalence vary greatly and are thought to be inaccurate (HallerKikkatalo et al. 2015). POF contributes to female infertility, decreased circulating ovarian
hormones, and increased risk of developing osteoporosis and heart disease (Lokkegaard
et al. 2006).

1.4.6 Evidence of ovarian disruption linked to EDCs
Although limited, controlled animal and epidemiological data are available that
suggest adverse female reproductive effects as a result of EDC exposure. One study
found that female rats exposed to three different doses of BPA (0.25-0.62mg/kg, 2.5-6.2
mg/kg or 25.0-62.5 mg/kg) subcutaneously from postnatal day 1 to postnatal day 10
experienced hormonal and reproductive changes that manifested at 4-5 months of age.
Rats exposed to the two highest doses had significantly increased testosterone and E2
serum concentrations, which altered GnRH secretion in the hypothalamus; furthermore,
all treatment groups had significantly decreased progesterone serum concentrations
(Fernández et al. 2010). Animals treated with 25.0-62.5 mg/kg BPA had large numbers of
ovarian cysts, cystic follicles and decreased numbers of total ovarian structures. These
animals were also unable to ovulate or produce pups; animals treated with 2.5-6.2 mg/kg
had significantly smaller litters when mated, consistent with decreased ovulatory
responses at this dose as well. Collectively, these results suggest that administration of
BPA at relatively high doses during neonatal development can result in symptoms
consistent with PCOS and cause disruption of the HPO axis.
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Another study observed disruption in follicular formation in rhesus monkeys
exposed orally to 400 μg BPA/kg body weight/day late in the third trimester of fetal
development when follicle formation occurs. This dose was demonstrated to produce
peak serum levels of 2–5 ng/mL BPA, which is in the range of what has been reported in
humans (Hunt et al. 2012). Animals treated daily with BPA had significantly increased
numbers of multioocyte follicles (MOFs) and disrupted synaptic recombination between
homologous chromosomes during meiosis. A large range of estrogenic exposures can
induce MOFs (reviewed by (Pepling 2012)), and similar results showing MOFs induced
by EDC exposures have been reported in mouse studies as well (Suzuki et al. 2002;
Zhang et al. 2012). It is unclear how MOFs occur, however it is hypothesized that a delay
in meiotic progression results in follicles that form before they undergo meiotic arrest and
therefore are not ready for enclosure, allowing for the inclusion of multiple immature
oocytes into one follicle. Reproductive outcomes as a result of MOFs are also unknown;
follicular growth failure is suspected (Hunt et al. 2012).
Several epidemiological studies have associated EDC exposures with increased
incidence of ovarian diseases. One study found that women diagnosed with PCOS had
significantly higher serum BPA concentrations than similar women without PCOS (cases
and controls, respectively) (Takeuchi et al. 2004). It was also observed that increasing
serum androgen levels correlated with increasing serum BPA levels, suggesting that BPA
concentration in blood is associated with a hyperandrogenic environment. Although the
relationship between androgen and BPA concentrations in the blood is unclear, it is
hypothesized that BPA is able to displace endogenous sex hormones from sex hormone
binding globulin (SHBG) sites since it is a known SHBG ligand; this would lead to a
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disruption in the androgen-to-estrogen ratio (Déchaud et al. 1999; Takeuchi et al. 2004).
Similar results showing associations between increased BPA and androgen serum
concentrations were found in another population of women diagnosed with PCOS
(Kandaraki et al. 2010). It has been reported that BPA metabolism and excretion is down
regulated by androgens through uridine diphosphate-glucuronosyl transferase activity in
the liver (Takeuchi et al. 2006), providing further evidence for a complicated relationship
between BPA and androgens.
Multiple human studies have observed adverse female reproductive health effects
associated with exposure to other EDCs including PCBs, phthalates, and hormonally
active pesticides (reviewed by (Mendola et al. 2008)). In short, these studies have found
associations between EDC exposures and decreased age of menarche and puberty in girls,
irregular menstrual cycles, irregular concentrations of circulating sex steroid hormones
and adverse pregnancy outcomes (Mendola et al. 2008).
In addition to the cases discussed above, Peretz and colleagues reviewed all
studies published between 2007-2013 that examined the impact of BPA on the male and
female reproductive systems (Peretz et al. 2014). In summary, studies using various
animal and cellular models as well as human data observed disturbances of the ovary in
three categories: 1) oogenesis and ovarian follicle formation; 2) steroidogenesis in
females; and 3) the quantity, quality and fertilization capacity of oocytes. Major findings
from these three categories include: 1) Low dose BPA exposure decreased the number of
primordial follicles in a dose-dependent manner in mice, induced changes in gene
expression in germ cells in mice and disrupted meiosis in mice and macaques (Hunt et al.
2012; Lawson et al. 2011; Zhang et al. 2012). 2) Similar to the findings of Fernandez and

25

colleges, postnatal BPA exposure increased E2, testosterone and progesterone levels in
mouse serum (Fernández et al. 2010; Tan et al. 2013). 3) Human studies reveal
correlations between serum BPA concentrations and oocyte maturation as well as
decreased developmental potential of oocytes (Fujimoto et al. 2011). Increasing urinary
BPA concentrations are also correlated with decreased number of mature oocytes and
fertilized oocytes (Mok‐Lin et al. 2010). Collectively these studies provide significant
evidence that BPA exposure disrupts reproductive fitness of the ovary in laboratory
animals, and similar relationships may be present in exposed humans.

1.5 Developmental Origins of Health and Disease (DOHaD)
The “developmental origins of health and disease” (DOHaD) hypothesis, also
known as the Barker hypothesis, recognizes that exposure to environmental stressors
during specific windows of development can result in permanent adverse health
outcomes, often in the form of non-communicable diseases, later in life (Barker 1995;
Barouki et al. 2012). The association between inadequacies during fetal life and later
onset of disease was proposed by David Barker, who in the 1980s discovered increased
risk of cardiovascular and metabolic diseases due to insufficient nutrition during
development as a result of the Dutch famine (Barker 2007). Developmental plasticity
allows organisms to adapt and respond to their surrounding environment in order to
improve survival and reproductive capability (Barouki et al. 2012). Differentiation and
development of cells and tissues occurs during time frames of development that are
specific to the particular organ or tissue that is being formed. Exposure to a variety of
environmental factors including drugs, inadequate nutrition, stress, environmental
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chemicals and other environmental factors during “critical windows of development” can
alter cellular and epigenetic programming of specific tissues and organs including the
ovary (Heijmans et al. 2009; Heindel and Vandenberg 2015).
Many chemicals are able to cross the placental barrier and enter the fetal
circulation and/or the surrounding fetal environment including the amniotic fluid;
therefore the developing organism can experience exposure to these compounds in utero
(Arbuckle 2010; Woodruff et al. 2011). Furthermore, as mentioned previously, many
environmental chemicals are highly lipophilic molecules that can bioaccumulate within
adipose tissue and can be transferred to developing offspring through breast milk,
resulting in exposure during critical postnatal periods of development. Persistent
environmental chemicals found in breast milk globally have been reviewed in depth by
several reports (Fürst 2006; Solomon and Weiss 2002). A recent study revealed that at
least 100 chemicals are present in the cord blood of infants, which suggests that fetal
exposure to an array of environmental chemicals including EDCs occurs during fetal
development (Unuvar and Buyukgebiz 2012). Many studies have been performed which
link developmental exposure to various EDCs to adverse female reproductive health
outcomes (reviewed by (Crain et al. 2008)). The DOHaD hypothesis has been applied to
explain the associations between developmental exposures to EDCs and increasing rates
of reproductive diseases and dysfunctions including subfecundity, PCOS, uterine
fibromyoma and some types of reproductive cancers (Barouki et al. 2012).
The DOHaD concept has become a well-recognized framework for modeling how
environmental chemicals and other environmental factors could contribute to the
increasing rates of chronic disease that the world’s human populations are experiencing
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including type II diabetes, obesity, cardiovascular disease and various types of cancer
(Barouki et al. 2012). Currently, non-communicable diseases are the most prominent
causes of death in industrialized countries, making the study of environmental chemicals
an important public health issue. Importantly, the DOHaD hypothesis provides new
strategies and implications to improve research and disease prevention measures by
creating a focus on the timing of disease (Barouki et al. 2012; Heindel and Vandenberg
2015); if DOHaD is sufficient to explain the associations between environmental
chemicals and later life diseases, limiting exposures to environmental toxins during
pregnancy and childhood could prevent chronic diseases in adulthood thus, decreasing
the global burden of non-communicable diseases.
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CHAPTER 2
PROJECT RATIONALE
Throughout the past several decades an overwhelming amount of scientific data
has been published regarding EDC exposures and related negative health outcomes.
EDCs differ greatly from other classes of environmental chemicals, posing complex
questions regarding the understanding of biological and physiological actions and effects
of EDCs, and creating debate in the scientific community. Current risk assessment
methods assess chemicals as if they follow a classic linear dose-response model,
assuming that low doses are less harmful than higher doses. At least some of the time,
EDCs defy this expectation; diverse adverse health effects are often induced at low doses.
BPS and TBBPA are ubiquitous in the environment and are structurally similar to
the EDC BPA, which has an array of known negative health outcomes associated with its
exposure. The use of these chemicals is largely unregulated and human populations
globally are exposed on a daily basis. The public health and environmental concern at
hand is the potential of negative health effects to arise due to BPS and TBBPA exposure.
When looking at this issue from a DOHaD lens, this issue is especially concerning to
pregnant women and children who face exposure during critical developmental windows.
In this report, I analyze the results observed from exposing mice perinatally to
BPS and TBBPA by looking at developmental endpoints relevant to ovarian development
and a small number of additional estrogen-sensitive endpoints. The chemicals BPS and
TBBPA are hypothesized to act as EDCs based on previous exposure reports and their
similarity in structure to BPA, a well-studied EDC; this is the major rationale for the
selection of BPS and TBBPA for this study.
29

The ovary was chosen as the organ of study for two main reasons: 1) The ovary is
an organ that is highly sensitive to hormones and EDCs therefore, if hormonal disruption
is taking place, we would expect to see changes within the ovary. 2) The ovary is
involved in the complex HPO axis, which provides strict control of multiple hormones
via positive and negative feedback systems. If hormone disruption occurs at any of the
three organs involved in the HPO axis (hypothalamus, pituitary, ovaries), we would
expect to see changes in the ovary. Observed endpoints were carefully selected in order
to observe potential changes in the ovary at a gross, cellular and molecular level. Gross
alterations were assessed during necropsy by looking for abnormalities such as ovarian
cysts and measuring uterine weight. Changes at the cellular level were assessed through
histological analysis of ovarian sections. Finally, immunohistochemistry and qPCR
provided data regarding changes in the ovary at a molecular level via protein and gene
expression analysis.

2.1 Hypothesis Statement
Based on previous studies that link developmental exposure to similarly
structured environmental EDCs to adverse female reproductive outcomes, I hypothesize
that developmental exposure to BPS and TBBPA will induce changes in estrogen
dependent endpoints such as ovarian development, with effects observed on a cellular
and molecular level. This supports an additional hypothesis that BPS and TBBPA are
capable of disturbing ovarian hormone functions via estrogen dependent pathways and
should be considered EDCs.

30

CHAPER 3
METHODS AND MATERIALS
3.1 Animals
Adult outbred CD-1 mice of both sexes were obtained from Charles River
Breeding Laboratories (Raleigh, NC). The CD-1 strain has previously been shown to be a
sensitive model for the use of reproductive endocrine disruption studies (Peretz et al.
2013). All procedures with mice were reviewed and approved by the Institutional Animal
Care and Use Committee at the University of Massachusetts, Amherst. Two females and
one male were housed together in a ventilated cage until pregnancy was confirmed via
the presence of a vaginal plug. Pregnant females were housed with up to two other
females of the same dosing group until pregnancy day 17. On pregnancy day 18, each
pregnant female was separated into her own cage in preparation for delivery. A 0600–
1800 hours light cycle and a controlled temperature of 25–27 °C was followed for the
entirety of the experiment. Standard rodent chow and water were provided for ad libitum
consumption.

3.2 Chemical administration
Females were randomly assigned to exposure groups using statistical methods to
ensure similar body weights across treatment groups. Females were ear-tagged upon
arrival to allow for their identification; identification tags were coded so that
experimenters were blind to treatment throughout the experiment.
The day that a vaginal plug was observed was considered embryonic day 1 (E1).
Pregnant females were orally dosed with 200g/kg of body weight/day of BPS in corn oil
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3.3 Tissue and body weight collection
Only female pups were used in this experiment. As mentioned above, two female
pups from each litter were sacrificed on PND22 (one treated with ethinyl estradiol, and
one treated with corn oil, from PND19-PND21). From these females, ovarian and uterine
tissues were collected; body weight was also measured at time of sacrifice. At 16 weeks
of age, 1-2 female pups from each litter were sacrificed, ovarian and uterine tissues were
observed for gross abnormalities, then collected as described below; uterine weight and
body weight were also measured. The remaining female pups were sacrificed at 24 weeks
of age, and ovarian and uterine tissues were collected and uterine weight was measured.
Individual body weight was again recorded on the day of euthanasia. At all ages, one
ovary and one horn of the uterus from each animal were frozen at -80°C for qPCR
analysis. The second ovary and the remainder of the uterus were fixed in neutral buffered
formalin for histological analysis.

3.4 Behavioral assessments
Females were assessed in an Open Field test at three different ages: PND22-24
(pre-puberty), 15 weeks, and 23 weeks of age. Briefly, the Open Field test involves the
placement of females in a clear plexiglass cage sized 40 cm x 40 cm x 40 cm. Females
were observed for 5 minute periods without experimenter intervention. At all three ages,
the Noldus Ethovision software was used to record basic parameters including: distance
traveled, average speed, and cumulative duration in the center of the apparatus. During
the 15 week and 23 week experiments, additional data was collected by hand including
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number of rears on walls, number of rears in the center of the open field, number of
crosses through the center of the apparatus, and time spent grooming.

3.5 Analysis of follicle formation
To characterize follicle formation, fixed ovaries from PND22 and week 16
females were processed through a series of alcohols and embedded in paraffin. Paraffin
blocks were sectioned at 5μm on a Fisher rotary microtome and mounted on positivelycharged glass slides. Sections were processed through a series of xylene and ethanol,
stained with hematoxylin and eosin, dehydrated, and coverslipped with permanent
mounting medium. Images were collected on a Zeiss AxioImager Inverted Microscope
with ZEN imaging software and a Zeiss high resolution color camera with a 20x EpiPlan
Objective.
To score follicles, every tenth section throughout the entire ovary was analyzed,
corresponding to one section per 50μm of ovary. In addition to the analysis of sections
from the entire ovary, four consecutive sections from the medullary region were analyzed
separately to minimize statistical error due to variation between ovarian sizes. Sections
were coded, allowing for scoring by a blinded observer. Follicles were scored using
methods modified from those described previously (Hunt et al., 2012) and categorized
into five categories depending on the stage of follicle development: primordial, primary
1, primary 2, secondary and antral (Figure 2). Follicles were scored as: “primordial” if
the nuclei were along the cortex of the ovary and had no granulosa cell formation;
“primary 1” if they had one layer of granulosa cells around the nucleus; “primary 2” if
they had two layers of granulosa cells but no theca cells around the nucleus; “secondary”
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if they had more than two layers of granulosa cells and at least one layer of theca cells
around the follicle; and “antral” if they had the same criteria of a secondary follicle with
the addition of a follicular fluid-filled antrum. Follicles of these various stages are shown
in Figure 2. The total number of oocytes, total number of follicles, and total number of
corpus lutea (when appropriate) were also counted for each section of ovary analyzed.

3.6 Immunohistochemistry
3.6.1 Technical methods
For each primary antibody of interest (Ki67, ER), one 5μm ovarian tissue
section per female was analyzed. In total, sections were analyzed from one female per
litter from each of the following groups: 1) at PND22 after three days’ treatment with oil;
2) at PND22 after three days’ treatment with ethinyl estradiol; and 3) at 16 weeks of age.
Ki67 antibodies were obtained from Vector Labs (rabbit polyclonal, Cat# VP-RM04) and
ERα antibodies were obtained from Millipore (rabbit polyclonal, Cat# 06-935).
Antibodies were first optimized for ovarian tissue and the optimum concentration found
for Ki67 and ER was determined to be 1:1000.
For immunohistochemical analysis, a protocol developed previously was
modified. Briefly, a series of xylene and ethanol washes was used to remove the paraffin
from the tissue. For antigen retrieval, microwave treatment paired with citric acid buffer
was used followed by a step for quenching endogenous peroxidase activity. Non-specific
antibody sites were blocked using normal goat serum 1:20 in 1.5% milk. After overnight
incubation with the primary antibody at 4°C, the tissue was incubated with the biotin
labeled anti-rabbit secondary antibody (Abcam Cat# ab64256) for one hour at room
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temperature, and the reaction was developed with streptavidin peroxidase complex
(Abcam Cat# ab64269). Finally, a color-change reaction was obtained using DAB (3,3diaminobenzidine, Abcam Cat# ab64238) and tissue was counterstained with
hemotoxylin before being cover-slipped with permanent mounting media.
3.6.2 Analysis
Each sample was imaged with a Zeiss AxioImager Inverted Microscope with a
20x EpiPlan Objective with ZEN imaging software and a Zeiss high-resolution color
camera. All analyses were conducted by an observer blind to treatment. When possible,
two of each follicle type with granulosa cells discussed above in section 3.5 (primary 1,
primary 2, secondary, antral) were analyzed. Follicles were analyzed by counting the
number positive/brown cells (both granulosa and theca cells were counted) and by
counting the number of negative/blue cells (again, both granulosa and theca cells were
counted). The total percentage of granulosa and theca cells that were positive for the
specific antibody being tested was then calculated (# positive / total number counted x
100). Corpus luteal cells were also analyzed (when appropriate) by counting the number
of positive/brown and negative/blue luteal cells. Total percent positive luteal cells were
calculated.

3.7 qPCR
3.7.1 RNA isolation from tissue
Ovaries collected from female mice described in Section 3.3 were homogenized
individually in Trizol to lyse cells and release RNA. Chloroform was added to each
sample and samples were then spun in a microcentrifuge at 4o for 15 minutes to separate
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the RNA from Trizol and RNA was precipitated with isopropanol, washed twice with
75% ethanol, and suspended in 50l of RNase-free water. The RNA concentration and
purity (260/280) was determined by Nano-drop. Samples were stored at -800.
3.7.2 cDNA synthesis
Reactions were performed in PCR tubes on ice using the iScript Reverse
Transcription Supermix for RT-qPCR kit (Cat 170-884, BioRad, Hercules, CA). Three
categories of reactions were carried out. The first category contained RNA samples that
underwent reverse transcription to produce cDNA. This reaction utilized 1g of RNA
from step 3.7.1 and 4g of 5x iScript RT supermix. The second category was a no reverse
transcriptase (NRT) control, to control for genomic DNA that may have contaminated the
sample. The NRT control contained 1g of RNA from step 3.7.1 and 4g of 5x iScript
RT supermix no RT control. A NRT control was made for each sample of RNA. The
third category was a no template (NT) control to control for the possible selfamplification of primers. The NT control contained 1g of reverse transcriptase. Only
two random NT controls were made since they were reused as controls. All samples were
run on a BioRad thermal cycler using standard temperature and time protocols: 25o for 5
minutes, 42o for 30 minutes, 85o for 5 minutes, 4o for . Samples were stored at -80o.
3.7.3 Primer design
The UCSC genome browser (genome.ucsc.edu) for mouse (Mus musculus) was
used to select nucleotide sequences of two sequential exons. The forward primer was
designed to sit on a selected exon of the gene of interest and the reverse primer to sit on
the very next exon downstream of the first selected exon. Primers were developed using
the Primer3Plus database (http://www.bioinformatics.nl/cgi37

bin/primer3plus/primer3plus.cgi/). The exon sequences recorded from the USCS genome
browers were used to generate forward and reverse primers. After primers were generated
in Primer3Plus, primer sequences were put into the UCSC BLAT search genome function
to verify that the primer sequences were 100% specific and that they lie on the correct
chromosome. Primer sequences are listed in Table 1 and are shown from 5’ to 3’.
3.7.4 qPCR
All reactions were assembled in eppendorf tubes on ice. For each sample of RNA,
a RT and NRT control sample were analyzed. For each qPCR run, one NT control sample
was analyzed. First, yeast tRNA was prepared by diluting 50ug/ml stock solution to a
1:200 dilution with dH20. Yeast tRNA was used to prevent cDNA from sticking to the
sides of the eppendorf tube. Next, cDNA samples from 3.7.2 were diluted 1:10 into yeast
tRNA made in the previous step. The supermix solution was then made by combining
10l iTaq Universal SYBR Green Supermix (Cat 172-5124, BioRad) and 3l of dH20 per
sample. The supermix solution was then evenly distributed into each of the tubes
containing cDNA and yeast tRNA, 15l of this solution was distributed into new
eppendorf tubes (enough tubes for each of the primers being analyzed.) The PCR reaction
mix contained 5l of the desired primer solution from 3.7.3 (containing both forward and
reverse primers) and 15l of the supermix solution, resulting in 20l of total solution for
each sample. Samples were briefly vortexed and spun in a centrifuge to condense all
liquid to the bottom of the tube. In a 384 well PCR plate, 5l of the PCR reaction mix
was pipetted into three consecutive wells and the plate was sealed with adhesive film.
PCR reactions were carried out with a BioRad CFX384 real time cycler using standard
temperature and time protocols.
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Table 1. Primer sequences used for qPCR analysis
Gene

Forward primer

Reverse primer sequence

sequence
Androgen
receptor/AR
Epidermal growth
factor receptor/EGFR
Estrogen
Receptorα/Esr1

AAG ACC TGC CTG ATC
TGT GG

TCG TTT CTG CTG GCA CAT
AG

TCT TCA AGG ATG TGA
AGT GTG

TGT ACG CTT TCG AAC AAT
GT

TGC AAT GAC TAT GCC
TCT GG

CTC CGG TTC TTG TCA ATG
GT

Estrogen
Receptor/Esr2

ACT GCC AAT CAT CGC
TTC TC

AGT AAC AGG GCT GGC ACA
AC

Insulin like Growth
Factor 1/IGF1
Progesterone
Receptor/PR

GGA CCA GAG ACC CTT
TGC GGG G

GGC TGC TTT TGT AGG CTT
CAG TGG

CCA GCA TGT CGT CTG
AGA AA

ACC ACA TCA GGC TCA ATG
CT

3.7.5 Analysis
cDNA amplification data was analyzed using Bio-Rad CFX manager software.
Samples were assured for quality of target cDNA amplification with the use of the
melting curve tool and amplification/Cq values. For each sample, the mean Cq value was
calculated for the three PCR wells that contained the sample. The mean sample Cq value/
level of gene expression was then normalized to mean Cq value/expression level of the
reference gene (B2M) from the same sample, resulting in a relative quantification value
(see, formula 1). Relative quantification values were then statistically assessed based on
animal treatment group.
Formula 1: Relative quantification value for the normalization of target gene
expression

Relative quantification= 2-Cq
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3.8 Statistical analysis
All statistical analysis was carried out with the use of SPSS statistical software
version 22. Effect of chemical treatment was assessed for mean uterine weights,
histological analysis of the ovary, immunohistochemical analyses in the ovary, and
ovarian gene expression with the use of an ANOVA test followed by a Bonferroni Post
Hoc test. Comparisons between oil vehicle and ethinyl estradiol treated females at
PND22 were conducted with independent samples T-tests. Graphs were made in excel,
and all graphs show mean ± SEM. Results were considered significant at p<0.05.
Statistical trends were identified as p>0.05 but <0.10.
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CHAPTER 4
RESULTS

4.1 Body and uterine weight
Body weight is a standard measure of animal health. In order to measure any
significant decrease in animal health potentially induced by chemical treatment, body
weight was measured before sacrifice at PND 22, 16 weeks and 24 weeks of age. No
notable changes in animal body weights were observed for either of the chemical
treatment groups in comparison to the control group or between chemical treatment
groups at any of the three measured ages (data not shown).
Wet (unblotted) uterine weight is a standard measure of estrogencity. To measure
estrogenic effects induced by chemical exposure, wet uterine weight was recorded at 16
and 24 weeks of age. Although we did not measure uterine weight at PND22, other
measures of estrogenicity (i.e. height of the uterine epithelium, expression of lactoferrin,
etc.) are being conducted in the Vandenberg laboratory by other researchers; the data
from these analyses are forthcoming. At both 16 and 24 weeks of age, no significant
changes in uterine weight were observed between the control and chemical treatment
groups. However, an ANOVA with Bonferroni post hoc test revealed a significant
difference between the BPS and TBBPA treated groups at 16 weeks of age (Figure 5A),
with mean uterine weights of BPS treated animals (0.169 g) that were significantly
heavier than the mean uterine weight of TBBPA treated animals (0.119g) (p=0.02). No
significant changes in uterine weight were observed at 24 weeks of age (Figure 5B).
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Since body weight was variable between individual animals, uterine weight: body
weight ratio was calculated. No significant differences were observed between treatment
groups for relative uterine weight at 16 or 24 weeks of age (Figure 5C,D).

4.2 Ovarian cysts
Ovarian cysts were determined based on gross morphology of the ovary during necropsy.
At PND22, cysts were not observed in any females in any treatment group. However, by
16 weeks, cysts were observed in 3/8 females treated with BPS, an increase compared to
the frequency of cysts in the vehicle-treated controls (0/5, see Table 2). At 24 weeks of
age, cysts were observed in all treatment groups but were more common in the TBBPA
and BPS-treated females compared to controls (Table 2).

Table 2. Frequency of ovarian cysts in females treated perinatally with test
chemicals
% with ovarian
cysts at 16 weeks
of age (n)
% with ovarian
cysts at 24 weeks
of age (n)

Controls

TBBPA

BPS

0% (5)

0% (6)

37.5% (8)

18.2% (11)

28.6% (7)

25% (8)

4.3 Open field behavior assessment
To assess potential changes in sexually dimorphic behaviors induced by chemical
exposure, female offspring were assessed at 15 and 23 weeks of age for a variety of
previously validated open field behaviors that provide information regarding sexual
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dimorphic behavior. Animals were scored by hand based on the following criteria in the
open field test: number of rears on walls, number of rears in the center of the open field,
number of crosses through the center of the apparatus, and time spent grooming
(described in 3.4). Additional criteria were scored by an automated system, Noldus
software, at PND22, week 15, and week 23 and included the total distance covered (cm)
by each mouse during the 5 minute trial, their mean velocity (cm/s), the percentage of
time the animal was moving, and the percentage of time the animal spent in a 5cm by
5cm square in the center of the open field.
4.3.1 PND 22
The Noldus software was used to measure four aspects of behavior in the open
field (Figure 6A). At this age, there were no significant differences between any
treatment groups.
4.3.2 Week 15
Significant changes in behavior were observed in four categories: center rears
(p=0.032), wall rears (p=0.029), center crosses (p=0.041) and total rears (p=0.010). For
all four categories, BPS-treated animals had increased measures compared to controls and
TBBPA had decreased measures compared to controls, although these differences were
not statistically significant (Figure 6B). Yet, in all four categories the specific behavior
was significantly increased in BPS treated animals compared to TBBPA treated animals.
Using the Noldus software, four quantitative measures were compared between
the three treatment groups, and similar trends were observed for distance travelled,
average velocity, and time spent moving: BPS treated females were typically more active
than controls, and TBBPA-treated females were typically less active than controls (Figure
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4.3.3 Week 23
No significant changes in behavior for the open field test were observed at 23
weeks of age between any treatment groups. There was a trend for a decrease in the
number of center crosses in the TBBPA-treated animals compared to control animals
although this was not statistically significant (Bonferroni, control vs TBBPA, p=0.092,
Figure 6D). The Noldus data has been collected but will be analyzed in the future.

4.4 Ovarian follicle formation
Based on the hypothesis that BPS and TBBPA are able to induce estrogenic
effects and thus induce premature ovarian development, we compared morphology of
ovarian follicles at PND 22 and 16 weeks of age from animals developmentally exposed
to vehicle, BPS and TBBPA. The method for follicle scoring is discussed in depth in
section 3.5.
4.4.1 PND 22
At PND 22, the follicle-score categories assessed included: primordial follicles,
primary 1 follicles, primary 2 follicles, secondary follicles and antral follicles (described
in detail in section 3.5). Follicles from every tenth section of the entire ovary as well as
follicles from only four sections of the medullary region were scored separately to
account for variability in ovarian size. Significant changes observed in follicle category
numbers from the entire ovary are shown in Figure 7, and from four sections in Figure 8.
Results from the analysis of every tenth section of the ovary are described as
follows: EE2 induced a significant increase in the number of oocytes throughout the
entire ovary in control (p=0.037) and TBBPA (p=0.001) treated animals (Figure 7A), and
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the number of follicles in control (p=0.024) and TBBPA (p=0.038) treated animals
(Figure 7B). These effects induced by EE2 were not observed in BPS treated animals. EE2
also induced a significant increase in the number of total secondary follicles in TBBPA
treated animals (p=0.001) and in control animals (p=0.053, Figure 7C). Again, EE2 failed
to increase the number of secondary follicles in BPS treated animals. An ANOVA
revealed differences in the number of secondary follicles between control, BPS and
TBBPA vehicle treated animals (p=0.082, Figure 7C). However, differences between
specific treatment pairs were not identified. In summary, the EE2 challenge increased the
number of total oocytes, secondary follicles and total number of follicles throughout the
entire ovary in control and TBBPA, but not BPS, treated animals.
Results from analysis of four consecutive sections from the medullary region of
the ovary are described as follows: An increase in oocytes in four sections was observed
for control animals (p=0.054) treated with EE2 (Figure 8A). An ANOVA with Bonferroni
post hoc analysis identified a significant difference between the number of oocytes in
four sections between EE2 challenged control and BPS treated animals (p=0.026, Figure
8A); the number of oocytes was significantly greater in the control group compared to
BPS-treated females. Similar to the results above, EE2 challenge also induced significant
increases in total number of follicles in four sections of control (p=0.04) and TBBPA
(p=0.013) treated animals (Figure 8B), and the number of secondary follicles in four
sections of control (p=0.016) and TBBPA (p=0.01) treated animals (Figure 8C). An
ANOVA revealed a trend in changes to the number of secondary follicles in four sections
between the three vehicle treatment groups (p=0.061) and a difference in the number of
total follicles in four sections between the three EE2 treatment groups (p=0.092) however,
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Table 3. Number of animals with MOFs visible in histological sections at PND22.
Postnatal
vehicle
Postnatal
EE2

Control
0/4

TBBPA
1/5

BPS
1/4

0/4

3/5

0/4

4.4.2 Week 16
At 16 weeks of age, follicle-score categories assessed included: primordial
follicles, primary 1 follicles, primary 2 follicles, secondary follicles, antral follicles and
corpus lutea (described in detail in section 2.5, see also Figure 2). Follicles from every
tenth section of the entire ovary as well as follicles from only four sections of the
medullary region were scored separately to account for variability in ovarian size. No
significant or notable changes in follicle scores were observed in relation to treatment at
16 weeks of age for assessment of every tenth section or four sections of the ovary (data
not shown).
Again, we examined the 16 week ovaries for the presence of MOFs. At this age,
MOFs were observed in all treatment groups including the controls (Table 4).

Table 4. Number of animals with MOFs visible in histological sections at week 16.
Control
2/4

TBBPA
2/4

BPS
1/5
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4.5.1 PND 22
EE2 induced a significant increase in Ki67 expression in primary 2 granulosa cells
in BPS treated animals (p<0.001, Figure 11A). An ANOVA with Bonferoni post hoc test
identified significant differences in Ki67 expression in primary 2 granulosa cells between
the three EE2 challenged treatment groups; the expression of Ki67 in the BPS treated
group was significantly increased compared to the control (p<0.001) and TBBPA
(p<0.001) treated groups (Figure 11A). In contrast, EE2 induced a significant decrease in
the level of Ki67 expression in secondary follicle theca cells and total theca cells in
TBBPA treated animals (Figure 11B,C). Additionally, there were treatment related
differences in ER expression of EE2 challenged animals for total percentage of ER
positive granulosa cells, although these did not reach statistical significance (ANOVA,
p=0.096, Figure 11D). Pairwise T-tests did not identify the differences between treatment
groups.
4.5.2 Week 16
There were no significant changes observed in Ki67 or ER expression at 16
weeks of age for any of the follicle categories scored (data not shown).
4.6 Analysis of ovarian gene expression via qPCR
To further quantify changes in ovarian development influenced by early life
chemical exposure, several genes which are crucial for hormone regulation in the ovary
were measured based on their expression levels in ovarian tissue with the use of qPCR.
Changes in ovarian gene expression levels were assessed for the following six target gene
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sequences: androgen receptor (AR), epidermal growth factor receptor (EGFR), estrogen
receptor α (ER), estrogen receptor β (ER), insulin like growth factor1 (IGF1) and
progesterone receptor (PR) (described in Section 2.8).
4.6.1 PND 22
EE2 induced a significant decrease in EGFR and ER expression in animals
exposed to BPS during prenatal development (p=0.003, Figure 12A, B). Significant
changes in EGFR expression based on prenatal treatment were also noted; BPS treated
animals exposed to vehicle at pre-puberty had significantly higher levels of EGFR
expression compared to control animals (Bonferroni, p=0.023) and TBBPA treated
animals (p= 0.034, Figure 12A) also exposed to vehicle. A significant increase in ER
expression levels was also observed in BPS treated animals compared to TBBPA treated
animals (p=0.05, Figure 12B). Significant differences based on treatment were not
observed for AR (Figure 12C), ERα (Figure 12D), IGF1 (Figure 12E), or PR (Figure
12F).
4.6.2 Week 16
There were no significant or notable differences in ovarian gene expression at 16
weeks of age for any of the genes examined (Figure 13).
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CHAPTER 5
DISCUSSION
5.1 Body and uterine weight
Classic toxicological animal studies often assess risk associated with chemicals
based on outcomes such as changes body weight, as this outcome is described in
internationally recognized guideline studies (Catanese et al. 2015; Myers et al. 2009b)
However, this measure is now viewed as an extreme health outcome since large doses of
chemical are often needed to obtain a significant fluctuation in body weight. Here,
significant changes in body weight of animals exposed to either BPS or TTBPA were not
observed. Environmentally relevant, low-doses of chemical were administered in this
study since BPS and TBBPA are suspected EDCs, and many modern EDC studies aim to
examine doses below the toxicological no observed adverse effect level (NOAEL)
(Vandenberg et al. 2012). Therefore, we did not expect to see changes in body weight as
an outcome of chemical exposures since these classical signs of toxicity are only
anticipated at higher doses.
To our knowledge, studies assessing changes in rodent body weight as a result of
BPS exposure have not yet been conducted or reported. However, it has been shown
previously that no significant changes in body weight were observed in rats exposed to
TBBPA or BPA postnatally (Choi et al. 2011) or perinatally (Bo et al. 2010; Tada et al.
2006), although many other studies have shown increases in body weight and more
sensitive measures of adiposity in rodents exposed to BPA during early development,
reviewed in (Rubin and Soto 2009). Thus, assessments of the effects of EDCs on body
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weight are complicated, and should consider whether weight gain and weight loss are
both toxicologically relevant hazard assessment outcomes.
The uterus is particularly sensitive to estrogen since E2 is responsible for
stimulating proliferation of the endometrium and enlargement of the uterine glands
during normal reproductive cyclicity (Kovacs and Ojeda 2011). Recommended tests
issued by the Endocrine Disrupter Screening and Testing Advisory Committee
(EDSTAC) of the U.S. Environmental Protection Agency (U.S. EPA) include what is
known as the “uterotrophic response assay” as the preferred in vivo screening method for
measuring estrogenicity and anti-estrogenicity of chemicals in rodents (Padilla-Banks et
al. 2001). This method is a part of “tier 1” of a two tiered testing protocol meaning that a
positive uterotrophic assay would require further testing as a part of “tier 2” (Zoeller et al.
2012). Briefly, this method compares wet weights of uteri from pre-pubertal female
rodents exposed to a chemical of interest and compares the exposed uterine weights to the
wet uterine weights from pre-pubertal females exposed to a known estrogenic compound
such as EE2 (positive control). If the chemical of interest induces a significant increase in
uterine weight, similar to that induced by the positive control, that chemical may then be
categorized as an estrogenic compound. In an alternative version of the uterotrophic
assay, animals may be ovariectomized, then exposed to a chemical of interest; if the
uterine weight increases significantly, the chemical may then be categorized as an
estrogenic compound. In our study, we did not ovariectomize the animals, allowing us to
preserve the ovaries for study, as uterine weight was not among the primary endpoints of
interest.
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Unfortunately, we did not weigh the uteri collected from females at PND22. To
overcome this, another student in the laboratory is measuring additional endpoints that
are predictive indicators of estrogen exposure such as height of the uterine endometrium,
volume fraction of the uterine compartments, and expression of estrogen-sensitive
proteins such as lactoferrin (Vandenberg et al. 2006). These data are forthcoming. At 16
weeks of age, we observed a significant change in uterine weight; animals exposed to
BPS had significantly heavier uteri than animals exposed to TBBPA. However, we did
not account for estrous cycle stage, which can drastically influence uterine weight. Thus,
our results could simply be due to differences in the estrous cycle stage when animals
were killed.
Further, because animal body weights varied, the relative uterine weight (uterine
weight/body weight) was calculated for each animal to account for variability in body
weight. No significant differences were observed for relative uterine weight for any
treatment group. This could mean that the significant difference observed in absolute
uterine weights between BPS and TBBPA treated animals may be attributed to
differences in total body size, rather than specific effects of these compounds on uterine
weight.
Previous studies show that prepubertal uteri are more sensitive to estrogen
stimulation than uteri from adult animals (Kang et al. 2000; Padilla-Banks et al. 2001).
Based on this information, it is possible that we did not observe significant changes in
body/uterine weight ratios due to the age of the animals. It has been previously shown
that TBBPA exposure during the perinatal period did not induce changes in uterine to
body weight ratios at PND27 in rats (Tada et al. 2006). Although we cannot say whether
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or not changes in uterine weights would be induced by perinatal BPS or TBBPA
exposure when organs were collected at PND 22, it is likely that pre-pubertal EE2
treatment would induce an increase in uterine weight. In fact, the timing of EE2
treatment and the dose we utilized were both selected to induce a uterotrophic response;
our major goal was to understand whether perinatal exposure to BPS or TBBPA would
alter the estrogen-sensitive responses to this pubertal EE2 challenge.
Although the EPA currently uses the uterotrophic assay to assess estrogenicity
and anti-estrogenicity of chemicals, this method has stirred debate from endocrine and
environmental health experts who suggest that the method is not sensitive enough to
reliably measure estrogen inference caused by environmental chemicals (Zoeller et al.
2012). For example, chemicals with known endocrine disrupting properties at low doses
including BPA and PCBs fail to induce uterotrophic response at the same low doses that
induce other adverse health outcomes such as uterine tumors (Newbold et al. 2009;
Rajapakse et al. 2002). The uterotrophic assay also fails to account for the increased
sensitivity to estrogens after developmental exposures since fetal and neonatal exposures
are not tested in this assay. Fetuses and neonates are more sensitive to environmental
chemicals than adults, with effects often seen at doses hundreds or thousands of times
lower than the doses required to observed uterotrophic responses in pubertal or adult
ovariectomized animals (Markey et al. 2001), and see also discussion of the DOHaD
hypothesis in section 1.5. It has been shown that fetal exposure to low doses of BPA
results in adverse health effects later in life including preneoplastic mammary lesions that
are not observed at high doses (Durando et al. 2007; Murray et al. 2007). Effects due to
developmental and low dose chemical exposures are completely overlooked by
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regulatory measures of estrogenicity by the endocrine disrupter screening program
(EDSP). For these reasons, endocrinologists view the uterotrophic assay as unfit to
optimally measure estrogenic effects induced by environmental chemicals (Zoeller et al.
2012).

5.2 Behavioral effects induced by perinatal chemical exposure
It has been shown previously that perinatal exposure to estrogenic chemicals such
as BPA can induce alterations in the number of neurons and expression of genes in
sexually dimorphic regions of the brain and thus lead to changes in sexually dimorphic
behaviors in assays including the open field test (Patisaul et al. 2006; Rubin et al. 2006).
Behavior data from open field tests in rodents suggest that females have a higher rate of
activity in comparison to males (Archer 1975; Blizard et al. 1975). Classical
endocrinology studies revealed that the aromatization of testosterone to estrogen during
fetal development is required for the development of male brain phenotypes in the male
rodent; thus, exposures of estrogens to females during these critical periods of
development can induce masculinization of these brain regions, and thus masculinization
of behaviors observed in the open field (Ogawa et al. 1997; Simerly 1989). A previous
study reported sexually dimorphic behaviors such as rears on wall, time spent in the
center of the field, and time stopped, in control animals; however, in animals that were
developmentally exposed to environmentally relevant doses of BPA, these sexually
dimorphic behaviors vanished with similar behaviors observed in males and females
(Rubin et al. 2006). This loss of sexual dimorphism appeared to be due to masculinization
of female behaviors, and feminization of male behaviors.
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Although our experiments did not compare behaviors between male and female
mice, our goal using the open field test was to identify potential differences in behavior
induced by developmental chemical exposure that could be indicative of alterations to
sexually dimorphic areas of the brain. The parameters measured in the open field test
were specifically chosen to measure activity level of the animals, with the expectation
that females exposed to exogenous estrogenic substances during development would
display decreased activity in the open field test, indicating masculinization due to
exposure.
In contrary to the previously mentioned BPA study (Rubin et al. 2006), the
behavioral data reported here do not suggest that females developmentally exposed to
BPS exhibit masculinized behaviors in comparison to control females at 15 weeks of age.
Instead, four parameters (center rears, wall rears, center crosses, total rears) suggest that
animals exposed to BPS have increased activity in comparison to the control, consistent
with hyperactivity. There is no evidence that we are aware of that behaviors in the open
field can be “hyper-feminized”, although that conclusion is also consistent with our
observations.
In contrast to the effects of BPS, females exposed to TBBPA had decreased
activity compared to the control. These findings could suggest that animals exposed to
TBBPA are masculinized to some degree, although additional behavioral measurements,
as well as investigations of sexually dimorphic regions of the brain, are also needed to
support such a conclusion.
Importantly, significant behavioral differences were not seen at 23 weeks of age,
although a notable decrease in the number of center crosses induced by TBBPA exposure
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compared to control animals could further support the hypothesis that developmental
exposure to TBBPA results in masculinization to some degree. It is plausible that the
behaviors observed in the open field were affected by the estrous cycle stage of the
females, which was not controlled in our study at either 15 or 23 weeks of age. Again,
additional study is needed here.

5.3 Effects on ovarian follicle formation, protein expression, and gene expression in
prepubertal animals (PND 22)
It has previously been reported that developmental exposure to estrogenic EDCs
such as BPA and DES result in abnormal ovarian follicle formation (Hunt et al. 2012; Li
et al. 2014; Rivera et al. 2011; Rodriguez et al. 2010; Wang et al. 2014). Based on the
hypothesis that BPS and TBBPA induce estrogenic effects and thus induce premature
ovarian development, we compared morphology of ovarian follicles at PND 22 from
animals developmentally exposed to BPS and TBBPA with ovarian follicles from
females exposed to oil only. Importantly, a critical part of our experimental design
included a pre-pubertal estrogen challenge. One female from each litter was treated with
oil and one was treated with 1 µg/kg/day EE2 for three days, from PND19-PND21. Prior
studies have revealed that developmental exposures to EDCs including BPA alter the
response of animals to hormonal or carcinogen challenges experienced later in life
(Durando et al. 2007; Prins et al. 2007; Wadia et al. 2007).
Pairwise T-tests of follicle formation data revealed that EE2 induced significant
follicular growth in TBBPA exposed and control animals at PND22 in the following
categories: total number oocytes, total secondary follicles and total number of follicles.
Follicular growth and/or development here is defined as the transition of primordial
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follicles to any other type of follicle with increased maturity in regards to the follicle
cycle (described in 1.4.1). We would expect to see an increase in follicular development
induced by EE2 since increased estrogen levels play a crucial role in the onset of puberty.
However, this induction of growth was not observed for animals exposed perinatally to
BPS and challenged with EE2. Based on our results, developmental exposure to BPS
alone induced follicular growth (observed in females at PND22 after pre-pubertal
treatment with oil vehicle); this was in contrast to control and TBBPA treated animals,
which required EE2 to induce follicular growth in the pre-pubertal period. Collectively,
these results suggest that perinatal exposures to BPS induce premature development of
the pre-pubertal ovary, and that additional estrogen exposures have no additive effect,
further suggesting that developmental BPS exposures disrupt normal estrogen regulated
pathways.
Further statistical analyses revealed that the number of oocytes in four sections of
ovary was significantly lower in BPS treated animals compared to control animals after
an EE2 challenge. These data also support our conclusion that a pre-pubertal estrogen
challenge provided by EE2 was not successful at increasing oocyte development in BPS
treated animals. Since the dose of EE2 we selected simulates estrogen levels experienced
during and after puberty, these data may suggest that the number of oocytes formed after
puberty could be significantly reduced in BPS-treated animals; these results may indicate
that BPS could pose a threat to the individual’s fertility since a decrease in the number of
oocytes directly correlates to decreased chances of fertilization.
Several published studies have reported significant changes in the number of
specific types of ovarian follicles induced by developmental exposure to BPA in mice,
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rats and lambs (Li et al. 2014; Rivera et al. 2011; Rodriguez et al. 2010; Wang et al.
2014). All of the studies above observed a significant decrease in the number of
primordial follicles after BPA exposure, which could be consistent with our results
suggesting that BPS causes an increase in ovarian maturation; increased ovarian
maturation would be expected to decrease the number of primordial follicles, although
we did not observe this specific measure. In contrast to our findings, one study observed
reduced numbers of primary, antral and total follicles in animals exposed to BPA
prepubertally (Li et al. 2014). To our knowledge, no studies using developmental EDC
exposures and a pre-pubertal estrogen challenge have been conducted using ovarian
endpoints, making it difficult to make further comparisons with our study.
Although these results were not statistically significant, BPS-treated females had
an increase in the numbers of secondary follicles compared to controls. Secondary
follicles are a measure of follicular maturity; because follicular maturation does not
normally occur until the onset of puberty, it may be concluded that BPS exposure alone
can advance follicular maturity. This data is similar to that of others who reported
increases in the number of growing follicles (primary and preantral) induced by
developmental BPA and DES exposure, consistent with the hypothesis that early life
exposures to estrogenic chemicals can stimulate the transition of primordial follicles to
more mature follicles (Rivera et al. 2011; Rodriguez et al. 2010).
Although time of puberty was not specifically recorded in these experiments, the
increase in follicle maturation suggests that puberty and ovulation in animals exposed to
BPS could possibly have been reached sooner than in control and TBBPA treated
animals. It has been reported that developmental exposure to BPA induces early onset of
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puberty in rodents (Nah et al. 2011; Nikaido et al. 2005; Wang et al. 2014). Increased
urinary BPA concentrations have also been associated with early onset of puberty in
humans (Caserta et al. 2014).
To further test the hypothesis that BPS and TBBPA are able to induce estrogenic
signaling pathways that prematurely induce ovarian development, we compared gene
and/or protein expression of factors that tightly regulate hormone action in the ovary at
PND 22. Immunohistochemistry was used to measure the expression of Ki67, a marker of
cell proliferation. EE2 treatment induced increases in the number of Ki67 positive
granulosa cells in specific follicle types in the ovaries of BPS exposed animals. Further,
these increases were significant when BPS treated animals were compared to either the
control or TBBPA treated groups. These data were surprising because they do not appear
to agree with the follicular data discussed above. Based on the follicle data, which
showed that EE2 induced follicular development in the control and TBBPA but not BPS
groups, we might expect to see no effect on measures of cell proliferation in animals
exposed to BPS and challenged with EE2. Instead, our results suggest the possibility that
the premature induction of ovarian development by BPS is independent of proliferation,
or the more likely possibility that BPS induced a wave of proliferation prior to our
assessment at PND22, and a second wave of proliferation is induced by the EE2 challenge
in these BPS-exposed females. Our immunohistochemical proliferation results are
somewhat consistent with previous studies that observed increased expression of Ki67 in
granulosa cells of growing follicles after developmental exposures to BPA or DES
(Rivera et al. 2011; Rodriguez et al. 2010).
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In addition to our analysis of proliferation in granulosa cells, our
immunohistochemical analysis revealed fewer Ki67 positive theca cells in secondary
follicles and in the overall percentage of positive theca cells in TBBPA treated animals
after an EE2 challenge. These results are contrary to a previous study that reported an
increase in Ki67 expression in antral thecal cells as a result of BPA exposure. Our data
suggest that, at least for some measures in the ovary, TBBPA exposures induce different
effects than either BPA or BPS; our data, as well as results from a number of prior
studies, are consistent with the hypothesis that both BPS and BPA act similar to estrogen.
Thus, our data suggest that developmental exposures to TBBPA alters ovarian
development via mechanisms that are distinct, and perhaps even independent of estrogen
receptor signaling.
Both immunohostochemistry and qPCR analyses were used to quantify the
expression of ER, one of the two main types of nuclear receptor activated by estrogen to
mediate estrogenic effects in ovarian follicles (Peretz et al. 2012). Although qPCR is
widely accepted as a reliable measure to quantify gene expression,
immunohistochemistry was performed to allow visualization of potential changes in ERα
expression in specific types of cells and follicles. Our analyses revealed that EE2 induced
an increase in the percentage of ER positive granulosa cells in animals exposed to BPS,
although this increase was not statistically significant. Further, ovaries from animals
exposed to BPS with and without an EE2 challenge showed a trend of increased ER
expression in many follicle categories compared to control and TBBPA treated groups.
However, no significant changes in ER expression were observed with qPCR. Previous
studies examining ER expression via immunohistochemistry and qPCR after BPA
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exposures have shown similar mixed findings; some studies demonstrate increased ER
expression after BPA exposure (Rodriguez et al. 2010) while others did not observe any
changes in ER expression induced by BPA (Rivera et al. 2011; Veiga-Lopez et al.
2013). Yet, these prior studies may shed light on how an estrogenic compound can
influence ER protein expression, measured by immunohistochemistry, and not influence
expression of the ER gene, Esr1. In-vitro timecourse experiments have shown that the
effects of BPA on ER expression are time dependent; these studies have also concluded
that BPA does not mediate follicular growth through ER, but via disruptions to other
aspects of the cell cycle (Peretz et al. 2012). In fact, ER itself has been shown to play
little or no role in follicular development parameters (Hegele-Hartung et al. 2004).
The other main nuclear receptor that regulates estrogenic effects in ovarian
follicles and drives granulosa cell proliferation is ER (Peretz et al. 2012). We observed
that perinatal exposure to BPS increased ER expression (Esr2) in the whole ovary
compared to control and TBBPA treated animals. Yet, EE2 challenge caused a decrease
in Esr2 expression in BPS-treated females. This data may help explain the results we
observed for the effects of BPS on follicular data discussed above, where BPS exposure
increased the number of advanced follicles. An increase in ER expression is consistent
with an increase in follicle growth (Peretz et al. 2012). Our findings also agree with prior
studies which revealed an increase in ovarian ER expression as a result of BPA
exposure (Brieno-Enriquez et al. 2012; Peretz et al. 2012; Rodriguez et al. 2010). Some
previous studies have concluded that BPA acts as an ER antagonist, and via these
actions can disturb ovarian follicular development (Brieno-Enriquez et al. 2012; Hunt et
al. 2003; Susiarjo et al. 2007). In fact, it has been noted that ovarian meiotic defects
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induced by developmental BPA exposure are nearly identical to those observed in ER
knock-out mice, highlighting the crucial role of ER function in ovarian development
(Susiarjo et al. 2007). Our findings mirror those induced by BPA, suggesting that BPS
also acts as an estrogen antagonist and may be able to bind to ER, thus inducing
downstream changes which result in the disturbance of ovarian follicular development.
Finally, our findings agree with the hypothesis that ER mediates direct estrogen effects
on ovarian follicular development (Hegele-Hartung et al. 2004). The antagonistic actions
of BPS on ER could inhibit endogenous estrogen activation of ER, thereby disrupting
negative feedback; ovarian cells may compensate for the loss of ER function by
increasing ER expression, consistent with the increased Esr2 expression shown here.
Similar to the ER expression results discussed above, BPS exposure also
increased expression levels of epidermal growth factor receptor (EGFR) compared to
control animals. It has been shown that EGFR expression increases late in
folliculogenesis, consistent with our finding of increased numbers of mature follicles in
BPS treated animals (El-Hayek et al. 2014). The increase in EGFR expression due to BPS
exposure may have serious implications. Increased expression of EGFR is a characteristic
of ovarian carcinoma; EGFR over expression is present in 25-50% of all ovarian cancers
(Lafky et al. 2008). Our data suggests that BPS may have malignant effects in regard to
ovarian development and poses a public health concern. Yet, importantly, treatment with
an EE2 challenge decreased EGFR expression in BPS-treated animals.
EGFR expression is critically regulated by E2; both estrogen and FSH stimulate
EGFR expression in granulosa cells, and the LH surge that is responsible for ovulation
releases ligands that activate EGFR in granulosa cells (El-Hayek et al. 2014; Garnett et
70

al. 2002). These factors suggest several plausible phenomena: First, BPS may be able to
act as an estrogen to stimulate increased EGFR expression in granulosa cells.
Alternatively, BPS may be able to induce an LH surge in BPS treated animals, which
would further explain the increase in EGFR expression. The observed effects induced by
BPS exposure including increased EGFR and ER expression, in combination with data
showing increased follicular maturation, go hand in hand; follicular growth is dependent
on estrogen activation of ER and puberty induces follicular growth and increased EGFR
expression in granulosa cells.

5.4 Effects on follicle formation, protein expression, and gene expression in adult
animals (16 weeks)
In order to capture effects that develop later in life after developmental chemical
exposure, the same criteria that were evaluated at PND 22 were also tested at 16 weeks of
age. In contrast to the many effects observed in the ovary at PND22, few effects of BPS
or TBBPA were observed in adulthood. At 16 weeks of age, no effects were observed on
gene expression, cell proliferation, or follicle stages. Slight effects may exist for
frequency of ovarian cysts, which was raised in BPS-treated animals compared to
controls at this age.
Previous studies that have examined developmental EDC exposure and related
ovarian outcomes have largely failed to examine ovarian endpoints later in life. Instead,
these studies have focused on ovarian development in fetal and/or prepubertal animals.
This lack of historical information makes it difficult to interpret the data found here.
Epidemiological studies focusing on precocious puberty induced by
developmental exogenous estrogen exposures report varied negative health effects once
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these affected individuals reach adulthood (reviewed in (Unuvar and Buyukgebiz 2012)).
It is plausible that the adult age assessed here (16 weeks) was too young to see subtle
effects on the reproductive system. We plan to assess tissue from 24-week-old animals
from the same cohort in order to determine whether the significant changes observed at
PND 22 correlate with additional changes at a time point even later in life. On the other
hand, several rodent and epidemiological studies have found an association between EDC
exposure and impaired fertility (Peretz et al. 2014; Souter et al. 2013). To our knowledge,
to the effects of BPS or TBBPA on fertility or fecundity has not yet been explored;
additional studies are needed to confirm actual effects on fecundity, such as reduced litter
size, reduced numbers of litters, and altered time to achieve pregnancy (Cabaton et al.
2011) .
The contrast in effects seen at PND 22 and week 16 may also be due to
differences in circulating hormone levels before and after puberty. At PND 22, mice
typically have not yet entered the pubertal window of development. During this window,
sex steroid hormones are low and start to increase in preparation for the onset of puberty.
With the very low production of estradiol prior to puberty (typically onset after PND25 in
female mice), we can conclude that the effects seen at PND 22 were induced by an
exogenous factor that has estrogenic function since the measured endpoints of interest
were estrogen dependent. Yet, at the onset of puberty, the ovary produces estradiol,
which initiates hormonal positive and negative feedback systems involving the ovary. It
is plausible that significant changes were not observed at 16 weeks of age because
endogenous estrogen levels were high enough to block the effects of early life BPS
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exposures. Control and TBBPA treated animals at 16 weeks of age would be “caught up”
in terms of sexual maturity and thus indistinguishable from animals treated with BPS.

5.5 Future directions
Future experiments will include analysis of the outcomes measured above for
animals of the same cohort at week 24 of age, focusing on follicular and gene expression
changes. Measures of ovarian aging will also be assessed with the use of TUNEL assay
for animals in each age group to quantify the number of apoptotic follicles induced by
treatment and age. Developmental BPA exposure has been shown to increase the number
of atretic follicles of the ovary (Li et al. 2014; Peretz et al. 2012; Rivera et al. 2011;
Wang et al. 2014). Additional measures of gene expression for genes indicative of normal
folliculargenesis including cyclin-dependent kinase (Cdk) inhibitor 1B (p27), and genes
responsible for ovarian development including Cyp19, the enzyme responsible for the
conversion of androgens into estrogens, and 5α-reductase, the enzyme responsible for the
conversion of testosterone into dihydrotestosterone, could be analyzed. Expression of
these genes in the ovary has been altered by developmental BPA exposure (Rivera et al.
2011; Rodriguez et al. 2010; Veiga-Lopez et al. 2013)
As mentioned above, in the long-term, determining whether BPS and TBBPA
alter measures of fertility and fecundity remains an important future research need. Not
only do these measures represent obvious adverse outcomes, they suggest possible
endpoints with public health implications. Further, analyses that examine additional
aspects of the HPO axis including gene expression in the hypothalamus and pituitary will
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also help to elucidate the mechanisms by which these compounds alter ovarian
development and responsiveness.

5.6 Conclusions
At the start of these experiments, it was not yet clear whether BPS or TBBPA
should be considered endocrine disrupting chemicals. In the last year, a number of studies
on BPS have suggested that developmental exposures to this compound induce altered
health outcomes in rodents and zebrafish (Rochester and Bolden 2015). The results
acquired through the experiments described here are fairly consistent with my initial
hypotheses that developmental exposure to BPS and TBBPA 1) induce changes in
estrogen-sensitive endpoints 2) disrupt cellular and molecular events in the developing
ovary and 3) act as estrogens.
My results are consistent with hypothesis 1; BPS and TBBPA are able to induce
changes in the ovary, an estrogen dependent endpoint. Hypothesis 1 is directly related to
hypothesis 2 in that, changes in ovarian development induced by BPS and TBBPA were
observed on both a cellular and molecular level. Majority of the cellular and molecular
effects observed here were a result of BPS exposure. At the cellular level, these changes
were most pronounced through the responsiveness of the ovary to a prepubertal estrogen
challenge, which revealed that BPS induces premature ovarian development and alters
the responsiveness of the ovary to EE2. At a molecular level, the estrogen challenge of
animals exposed to BPS revealed that these animals are still responsive to estrogens and
that this responsiveness may be mediated through ER, confirmed by qPCR data
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showing elevated ER expression. The ability of BPS to act via ER confirms my final
hypothesis of this chemical’s ability to act as an estrogen and therefore I would classify
BPS as an EDC. TBBPA on the other hand appears to act through a different mechanism
than BPS. Surprisingly, my study revealed that TBBPA also alters ovarian development
on the molecular level; however, these effects may be independent of actions via the
estrogen receptor. Majority of the molecular effects induced by TBBPA were observed in
theca cells that primarily produce androstenedione for granulosa cells to convert to
estradiol via aromatase. It is possible that TBBPA disrupts the production of androgens
and thus the synthesis of estradiol without directly binding to estrogen receptors. This
proposed mechanism of endocrine disruption induced by TBBPA is different than that of
BPS however; endocrine function is modified in both cases.
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